This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antman, E. M. Articles by Morrow, D. A. Search for Related Content PubMed Articles by Antman, E. M. Articles by Morrow, D. A. Related Collections Related Article

Editorials

Biomarker Release After Percutaneous Coronary Intervention

A Message From the Heart

Elliott M. Antman, MD and David A. Morrow, MD, MPH

From the TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Mass.

Reprint requests to Elliott M. Antman, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail eantman@rics.bwh.harvard.edu

Key Words: Editorials • biomarkers • myocardial infarction • troponin • angioplasty • transluminal • percutaneous coronary

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Cardiac biomarkers of necrosis provide clinicians with important "messages" from the heart. They are released into the interstitium of the myocardium after loss of the integrity of cardiac myocyte membranes. The pattern of the rise and fall of an individual biomarker (ie, its release kinetics) depends on its intracellular location in the myocyte, molecular weight, and clearance from the interstitium of the myocardium and ultimately the circulation.¹ Cardiac biomarkers play an integral role in the clinical diagnosis of myocardial infarction (MI). Referring to the spontaneous occurrence of MI in patients, the World Health Organization required that at least 2 of the following be present to fulfill the criteria for MI: a history of ischemia-type chest discomfort, evolutionary changes on serially obtained ECG tracings, and a rise and fall in serum cardiac markers.²

Article see p 10

See Editorial Circulation. 2008;118:609–611

See Article Circulation. 2008;118:632–638

Several dramatic advances have occurred in the biomarker component of the diagnosis of MI. Analytes with greater specificity for the myocardium were introduced into clinical medicine, with creatine kinase-MB replacing total creatine kinase and subsequently cardiac-specific troponins replacing creatine kinase-MB as the biomarker of choice for diagnosing MI.³ Assay technology improved as clinical chemists moved from enzymatic activity assays for CK to highly specific immunoassays that can detect progressively smaller concentrations of cardiac troponins in the peripheral circulation.⁴ Although ST-elevation MI (STEMI) is easily identified on the 12-lead ECG, we now recognize that many patients previously diagnosed with unstable angina are more properly diagnosed . . . [Full Text of this Article]

Related Article

Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention: An Analysis of Preintervention and Postintervention Troponin T Levels in 5487 Patients

Abhiram Prasad, Charanjit S. Rihal, Ryan J. Lennon, Mandeep Singh, Allan S. Jaffe, and David R. Holmes, Jr
Circ Cardiovasc Interv 2008 1: 10-19. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				Periprocedural Troponin Levels Predict Outcome of Percutaneous Coronary Intervention Journal Watch Cardiology, October 22, 2008; 2008(1022): 4 - 4. [Full Text]